The cASPerCF trial on optimal dosing of posaconazole in children and young people with CF and Aspergillus colonization was prematurely terminated due to poor patient recruitment, the impact of the COVID-19 pandemic, and the rollout of CFTR modulator therapy [178]. The gene discussed is CFTR; the disease is cystic fibrosis.